Literature DB >> 30596322

Should Researchers Offer Results to Family Members of Cancer Biobank Participants? A Mixed-Methods Study of Proband and Family Preferences.

Deborah R Gordon1, Carmen Radecki Breitkopf2, Marguerite Robinson3, Wesley O Petersen4, Jason S Egginton5, Kari G Chaffee2, Gloria M Petersen2, Susan M Wolf6, Barbara A Koenig7.   

Abstract

BACKGROUND: Genomic analysis may reveal both primary and secondary findings with direct relevance to the health of probands' biological relatives. Researchers question their obligations to return findings not only to participants but also to family members. Given the social value of privacy protection, should researchers offer a proband's results to family members, including after the proband's death?
METHODS: Preferences were elicited using interviews and a survey. Respondents included probands from two pancreatic cancer research resources, plus biological and nonbiological family members. Hypothetical scenarios based on actual research findings from the two cancer research resources were presented; participants were asked return of results preferences and justifications. Interview transcripts were coded and analyzed; survey data were analyzed descriptively.
RESULTS: Fifty-one individuals (17 probands, 21 biological relatives, 13 spouses/partners) were interviewed. Subsequently, a mailed survey was returned by 464 probands, 1,040 biological family members, and 399 spouses/partners. This analysis highlights the interviews, augmented by survey findings. Probands and family members attribute great predictive power and lifesaving potential to genomic information. A majority hold that a proband's genomic results relevant to family members' health ought to be offered. While informants endorse each individual's choice whether to learn results, most express a strong moral responsibility to know and to share, particularly with the younger generation. Most have few concerns about sharing genetic information within the family; rather, their concerns focus on the health consequences of not sharing.
CONCLUSIONS: Although additional studies in diverse populations are needed, policies governing return of genomic results should consider how families understand genomic data, how they value confidentiality within the family, and whether they endorse an ethics of sharing. A focus on respect for individual privacy-without attention to how the broad social and cultural context shapes preferences within families-cannot be the sole foundation of policy.

Entities:  

Keywords:  Return of results; ethics of disclosure; family communication; genomics; incidental findings

Mesh:

Year:  2018        PMID: 30596322      PMCID: PMC6443426          DOI: 10.1080/23294515.2018.1546241

Source DB:  PubMed          Journal:  AJOB Empir Bioeth        ISSN: 2329-4515


  57 in total

1.  Why not grant primacy to the family?

Authors:  B A Koenig
Journal:  Am J Bioeth       Date:  2001       Impact factor: 11.229

2.  Anticipate and communicate: Ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues).

Authors:  Christine Weiner
Journal:  Am J Epidemiol       Date:  2014-08-22       Impact factor: 4.897

3.  Attitudes Toward Return of Genetic Research Results to Relatives, Including After Death: Comparison of Cancer Probands, Blood Relatives, and Spouse/Partners.

Authors:  Carmen Radecki Breitkopf; Susan M Wolf; Kari G Chaffee; Marguerite E Robinson; Noralane M Lindor; Deborah R Gordon; Barbara A Koenig; Gloria M Petersen
Journal:  J Empir Res Hum Res Ethics       Date:  2018-04-27       Impact factor: 1.742

4.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma.

Authors:  Robert R McWilliams; Gloria M Petersen; Kari G Rabe; Leonard M Holtegaard; Pamela J Lynch; Michele D Bishop; W Edward Highsmith
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

5.  Personalized genomic medicine and the rhetoric of empowerment.

Authors:  Eric T Juengst; Michael A Flatt; Richard A Settersten
Journal:  Hastings Cent Rep       Date:  2012 Sep-Oct       Impact factor: 2.683

6.  ONE SIZE FITS ALL? ON PATIENT AUTONOMY, MEDICAL DECISION-MAKING, AND THE IMPACT OF CULTURE.

Authors:  Roy Gilbar; José Miola
Journal:  Med Law Rev       Date:  2014-12-16       Impact factor: 1.267

7.  The Double Helix: Applying an Ethic of Care to the Duty to Warn Genetic Relatives of Genetic Information.

Authors:  Meaghann Weaver
Journal:  Bioethics       Date:  2015-07-21       Impact factor: 1.898

8.  Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L.

Authors:  Robert R McWilliams; William R Bamlet; Mariza de Andrade; David N Rider; Julie M Cunningham; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-24       Impact factor: 4.254

9.  BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.

Authors:  David B Zhen; Kari G Rabe; Steven Gallinger; Sapna Syngal; Ann G Schwartz; Michael G Goggins; Ralph H Hruban; Michele L Cote; Robert R McWilliams; Nicholas J Roberts; Lisa A Cannon-Albright; Donghui Li; Kelsey Moyes; Richard J Wenstrup; Anne-Renee Hartman; Daniela Seminara; Alison P Klein; Gloria M Petersen
Journal:  Genet Med       Date:  2014-11-20       Impact factor: 8.822

10.  Clinical genome sequencing and population preferences for information about 'incidental' findings-From medically actionable genes (MAGs) to patient actionable genes (PAGs).

Authors:  Thomas Ploug; Søren Holm
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

View more
  8 in total

1.  Return of individual research results from genomic research: A systematic review of stakeholder perspectives.

Authors:  Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Mwenza Blell; Isabelle Budin-Ljøsne; Lorraine Cowley; Stephanie O M Dyke; Clara Gaff; Robert Green; Alison Hall; Amber L Johns; Bartha M Knoppers; Stephanie Mulrine; Christine Patch; Eva Winkler; Madeleine J Murtagh
Journal:  PLoS One       Date:  2021-11-08       Impact factor: 3.240

2.  "If relatives inherited the gene, they should inherit the data." Bringing the family into the room where bioethics happens.

Authors:  Deborah R Gordon; Barbara A Koenig
Journal:  New Genet Soc       Date:  2021-12-13

Review 3.  Views on genomic research result delivery methods and informed consent: a review.

Authors:  Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Madeleine J Murtagh
Journal:  Per Med       Date:  2021-04-06       Impact factor: 2.512

4.  Becoming and being a biobank donor: The role of relationships and ethics.

Authors:  Signe Mezinska; Jekaterina Kaleja; Ilze Mileiko
Journal:  PLoS One       Date:  2020-11-23       Impact factor: 3.240

5.  Health data research on sudden cardiac arrest: perspectives of survivors and their next-of-kin.

Authors:  Marieke A R Bak; Rens Veeken; Marieke T Blom; Hanno L Tan; Dick L Willems
Journal:  BMC Med Ethics       Date:  2021-01-28       Impact factor: 2.652

6.  Perspectives regarding privacy in clinical research among research professionals from the Arab region: an exploratory qualitative study.

Authors:  Latifa Adarmouch; Marwan Felaefel; Robert Wachbroit; Henry Silverman
Journal:  BMC Med Ethics       Date:  2020-04-15       Impact factor: 2.652

7.  Stakeholders' perspectives on the post-mortem use of genetic and health-related data for research: a systematic review.

Authors:  Marieke A R Bak; M Corrette Ploem; Hakan Ateşyürek; Marieke T Blom; Hanno L Tan; Dick L Willems
Journal:  Eur J Hum Genet       Date:  2019-09-16       Impact factor: 4.246

8.  Comparison of factors influencing the willingness to donate biospecimens among guardians of children with cancer and adult cancer patients.

Authors:  Hongxiang Gao; Baige Cao; Nan Dang; Song Gu; Min Xu; Bin Ji; Yiqi Shi; Shijian Liu; Congrong Wang
Journal:  Cancer Med       Date:  2022-02-03       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.